Tuesday, November 03, 2020 1:20:18 AM
It will be interesting to see the dosing regimen approved by the FDA.
We know Brilacidin has a long half life with a short time to virolysis.It also is effective in vitro at low doses. Will the FDA opt for 1,2 or 3 infusions or 2 arms with different doses?
My guess is 2 different doses given 2 or 3 infusions 2-3 days apart.
Fortunately they have experienced researchers to work these matters out.
What will the end points be? The in patient study most likely will evaluate treatment in hospitalized patients on low levels of oxygen without signs of imminent pulmonary failure.
If you are really confident the first end point will be lower mortality[ which no antiviral drug has achieved]if not time to recovery second will be reduced percentage to pulmonary failure or shorten tim oxygen was required and the last will be time to virus neutralization in hospitalized patients .
We should have more details of the human clinical trials in 2-3 weeks. The trial will be short.
For comparison review the Remdesvir Adaptive Covid-19 Treatment Trial (ACTT-1)trial:
https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
GLTA Farrell
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM